Key Points
- On April 10, Heartflow CEO John C.M. Farquhar sold 22,562 shares at an average price of $26.72 for about $602,856.64, cutting his stake by 3.95% to 549,163 shares; the sale was disclosed in an SEC filing and executed under a Rule 10b5-1 trading plan.
- Farquhar has sold additional tranches this year (Feb 10: 22,562; Mar 10: 12,837; Mar 18: 9,725), totaling 67,686 shares for roughly $1.76 million in proceeds, signaling a sustained pattern of insider selling.
- Heartflow stock opened at $29.05, sits near its 200-day SMA ($29.56) and above its 50-day SMA ($24.70), the company has a market cap of $2.49 billion and a consensus analyst rating of "Moderate Buy" with an average price target of $37.67.
Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) CEO John C.M. Farquhar sold 22,562 shares of the firm's stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $26.72, for a total value of $602,856.64. Following the sale, the chief executive officer directly owned 549,163 shares of the company's stock, valued at $14,673,635.36. The trade was a 3.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
John C.M. Farquhar also recently made the following trade(s):
- On Wednesday, March 18th, John C.M. Farquhar sold 9,725 shares of Heartflow stock. The shares were sold at an average price of $25.00, for a total transaction of $243,125.00.
- On Tuesday, March 10th, John C.M. Farquhar sold 12,837 shares of Heartflow stock. The shares were sold at an average price of $22.66, for a total transaction of $290,886.42.
- On Tuesday, February 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $27.46, for a total transaction of $619,552.52.
Heartflow Stock Performance
Heartflow stock opened at $29.05 on Wednesday. The company's 50 day simple moving average is $24.70 and its 200-day simple moving average is $29.56. Heartflow, Inc. has a 1 year low of $20.13 and a 1 year high of $41.22. The company has a market capitalization of $2.49 billion and a price-to-earnings ratio of -14.60.
Wall Street Analyst Weigh In
HTFL has been the topic of a number of research reports. Wells Fargo & Company decreased their price target on Heartflow from $38.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, March 19th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Heartflow in a research note on Monday, December 29th. JPMorgan Chase & Co. decreased their target price on Heartflow from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, March 19th. Finally, Canaccord Genuity Group raised their target price on Heartflow from $40.00 to $43.00 and gave the company a "buy" rating in a report on Thursday, March 19th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $37.67.
Read Our Latest Analysis on HTFL
Institutional Trading of Heartflow
Hedge funds have recently added to or reduced their stakes in the company. TFC Financial Management Inc. purchased a new position in Heartflow in the third quarter worth approximately $40,000. Emerald Mutual Fund Advisers Trust purchased a new stake in shares of Heartflow in the 3rd quarter valued at approximately $4,418,000. TrueMark Investments LLC acquired a new stake in shares of Heartflow in the 3rd quarter valued at $918,000. Baillie Gifford & Co. purchased a new stake in shares of Heartflow during the 3rd quarter worth $101,182,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Heartflow during the third quarter worth $234,000.
Heartflow Company Profile
(
Get Free Report)
HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.
HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
